Alyeska Investment Group
ACRS icon

Alyeska Investment Group’s Aclaris Therapeutics ACRS Stock Holding History

Alyeska Investment Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-167,208
Closed -$366K – 396
2019
Q2 		$366K Buy
+167,208
New +$911K ﹤0.01% 414
2018
Q3 		– Sell
-613,635
Closed -$12.3M – 401
2018
Q2 		$12.3M Sell
613,635
-238,139
-28% -$4.4M 0.11% 188
2018
Q1 		$14.9M Buy
851,774
+183,890
+28% +$3.9M 0.12% 188
2017
Q4 		$16.5M Buy
667,884
+200,000
+43% +$4.87M 0.13% 181
2017
Q3 		$12.1M Buy
467,884
+215,201
+85% +$5.77M 0.09% 226
2017
Q2 		$6.85M Buy
252,683
+59,726
+31% +$1.62M 0.06% 266
2017
Q1 		$5.75M Buy
192,957
+95,103
+97% +$2.74M 0.05% 301
2016
Q4 		$2.66M Buy
+97,854
New +$2.5M 0.02% 375

Other funds holding ACRS

Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group's ACRS Position: Q3 2019 in Review

Alyeska Investment Group sold out of Aclaris Therapeutics (ACRS) in Q3 2019, closing a stake of 167,208 shares — an estimated $366K sold.

Alyeska Investment Group first reported a position in ACRS in Q4 2016 and held it in 8 quarters. The position peaked at $16.5M in Q4 2017. 81 funds tracked by Wall St. Rank hold ACRS as of Q3 2019.

  • Alyeska Investment Group reported no remaining Aclaris Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Alyeska Investment Group sold 167,208 Aclaris Therapeutics shares in Q3 2019, an estimated $366K.
  • Alyeska Investment Group first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 8 quarters.
  • Alyeska Investment Group's Aclaris Therapeutics position peaked at $16.5M in Q4 2017.
  • 81 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2019.

Based on Alyeska Investment Group's 13F filing for Q3 2019, filed 14 Nov 2019.